Exploratory objectives
tumor
TUMOR

To evaluate efficacy as a function of PD-L1, TIGIT, CD155, and CD112 expressionTo evaluate the evolution of the in situ immune responseTo evaluate the evolution of the systemic immune responseTo evaluate the induction of neoantigen and tumor-shared antigen-specific immune responseTo evaluate the radiotherapy planning target volumes (PTV) impact on systemic immune responseTo create a research biosample repository (blood and tumor)